

肝炎文献リスト_2026 年 1 月号

岡本宏明

2026-01-1

Gaps in the hepatitis C prenatal and postpartum care cascade: Rationale for treatment in pregnancy

Mendlowitz A B, Flemming J A, Kushner T, Wong W W L, Greenwald Z R, Li W, Chen B, Kwong J C, Masterman C, Capraru C, Feld J J, Biondi M J

Clin Infect Dis ciaf578, Dec 9 [Epub ahead of print] PMID: 41363839

<https://doi.org/10.1093/cid/ciaf578>

C型肝炎の周産期ケアの連携におけるギャップ：妊娠中の治療の根拠

2026-01-2

Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal

Lens S, Burton A R, Davies J, Locatelli M, Garcia-Lopez M, Pocurull A, Jeffery-Smith A, Novikov N, Fletcher S P, Forns X, Perez-Del-Pulgar S, Maini M K

Gut 2024-333309, Dec 19 [Epub ahead of print] PMID: 41419306

<https://doi.org/10.1136/gutjnl-2024-333309>

治療中止によって引き起こされる HBV 感染の攪乱過程における B 細胞免疫の追跡

2026-01-3

Optimizing hepatitis C virus testing in the era of point-of-care RNA diagnostics

Helm E W, Kim H N, Greninger A L

J Clin Microbiol e01259-25, Dec 17 [Epub ahead of print] PMID: 41406031

<https://doi.org/10.1128/jcm.01259-25>

POC RNA 診断時代における HCV 検査の最適化

2026-01-4

Bioorthogonal click chemistry to visualize an immunogenic HLA-A2-restricted hepatitis B virus epitope in human monocyte-derived dendritic cells

Mostert T P, Kessler A L, Luijten R J, Doelman W, Isendoorn M M E, Filippov D V, van Kasteren S I, Buschow S I

J Immunol vkaf312, Nov 20 [Epub ahead of print] PMID: 41267163

<https://doi.org/10.1093/jimmun/vkaf312>

ヒト単球由来樹状細胞における免疫原性 HLA-A2 拘束性 HBV エピトープを可視化するための生体適合性クリック化学

2026-01-5

Oral microbiome diversity matters on nucleos(t)ide analogue cessation in chronic hepatitis B

Ghorbani M, Kvedaraite A, Al-Manei K, Too C B, Cederberg S, Johannessen A, Reikvam D H, Valentini D, Maucourant C, Bjorkstrom N K, Aleman S, Sallberg Chen M

J Infect Dis jiaf591, Dec 2 [Epub ahead of print] PMID: 41328917

<https://doi.org/10.1093/infdis/jiaf591>

慢性 B 型肝炎における核酸アナログ中止時の口腔内微生物叢の多様性は重要である

2026-01-6

Development of a rapid automated point-of-care test for hepatitis C viral RNA on the DASH® Rapid PCR System

Reed J L, Butzler M A, Hawkins C A, Manabe Y C, Holden J, Thomas D L, Cox A L, McFall S M

J Infect Dis jiaf608, Dec 10 [Epub ahead of print]

PMID: 41369203

<https://doi.org/10.1093/infdis/jiaf608>

DASH®迅速 PCR システムを用いた HCV RNA の迅速自動 POC 検査の開発

2026-01-7

A rapid assay for HCV RNA detection using RT-LAMP coupled CRISPR-Cas12b based strategy

Chowdhury A, Garcia B G, Zahoor M A, Fadl ElMawla N, Davidson A R, Wyatt H D M, Maxwell K L, Mahassine A, Gehring A, Feld J J

J Infect Dis jiaf609, Dec 16 [Epub ahead of print]

PMID:41397899

RT-LAMP と CRISPR-Cas12b を組み合わせた戦略を用いた HCV RNA 検出のための迅速アッセイ

2026-01-8

Transient interferon-driven NK cell activation in acute hepatitis C

Strunz B, Zhan Q, Khera T, Hengst J, Jankovic M, Deterding K, Niehrs A, Cornberg M, Xu C J, Wedemeyer H, Bjorkstrom N K

J Infect Dis jiaf654, Dec 27 [Epub ahead of print]

PMID: 41453396

<https://doi.org/10.1093/infdis/jiaf654>

急性 C 型肝炎における一過性 IFN 依存性 NK 細胞活性化

2026-01-9

The differential effects of immunosuppressants on hepatitis E virus replication and the triggered inflammatory responses in macrophages

Zhou J, Liu K, Boor P P C, Pan Q, Ayada I

J Viral Hepat 33(1): e70118, 2026

PMID: 41400072

<https://doi.org/10.1111/jvh.70118>

HEV 複製とそれに続くマクロファージにおける炎症反応に対する免疫抑制剤の差別的(種類によって異なる)効果

2026-01-10

Impact of double reflex testing and linkage to treatment on clinical outcomes of chronic hepatitis delta virus infection in the United States

Wong R J, Gish R G, Jacobson I M, Lim J K, Rock M, Kinyik-Merena C, Ma H, Smith N, Kim C

J Viral Hepat 33(1): e70119, 2026

PMID: 41405233

<https://doi.org/10.1111/jvh.70119>

米国における慢性 HDV 感染の臨床転帰に対する二重反射検査と治療連携の影響

2026-01-11

The current burden of hepatitis B in the United States: A state, territorial, and county modelling analysis

Razavi-Shearer D, Gamkrelidze I, Hall S, Cohen C, Gish R, Pham T, Razavi-Shearer K, Remak W, Saboui M, Voeller A, Wallace C, Razavi H

J Viral Hepat 33(1): e70122, 2026

PMID: 41416586

<https://doi.org/10.1111/jvh.70122>

米国における B 型肝炎の現状の負担: 州、準州、郡レベルのモデリング分析

2026-01-12

Molecular insights into the S gene of hepatitis B virus: Analysis among household contacts and clinical implications of mutations

Athalye S, Khargekar N, Panale P, Shinde S, Shankarkumar A, Banerjee A

J Viral Hepat 33(1): e70124, 2026

PMID:41424401

HBV S 遺伝子の分子レベルでの知見: 家庭内接触者における解析と変異の臨床的意義

2026-01-13

GRP75 blocks hepatitis E virus infection by targeting HEV-ORF2 for degradation through chaperone-mediated autophagy and promoting IRF3 activation

Wang Y, Li Y, Xu R, Yuan T, Xu C, Zhou Z, Ba C, Zhao Q, Wu C, An Z, Yin X, Yang Y, Nan Y

J Virol e01344-25, Dec 17 [Epub ahead of print]

PMID: 41405201

<https://doi.org/10.1128/jvi.01344-25>

GRP75 は、シャペロンを介したオートファジーによる HEV-ORF2 の分解を標的とし、IRF3 の活性化を促進することで、HEV 感染を阻害する

2026-01-14

A Phase 2 trial of tobevibart plus elebsiran in hepatitis D

Asselah T, Chattergoon M A, Jucov A, Streinu-Cercel A, Lampertico P, Wedemeyer H, Kennedy P T, Gane E J, Bullard B L, Chow S, Santos D, Camus G, Lu Y, Pilowa C, Hwang C, Correll T, Agarwal K

N Engl J Med oa2508827, Nov 9 [Epub ahead of print]

PMID:41211943

D 型肝炎に対するトベビバートとエレブシランの併用療法の第 2 相試験

2026-01-15

Netrin-1 inhibits the attachment and internalization of hepatitis B virus for hepatocyte infection

Wang Y, Murai K, Ishida A, Kawasaki N, Kuroki K, Li Y Y, Sato Y, Miura Y, Takara K, Kong L, Shimakami T, Nio K, Higuchi Y, Suemizu H, Ito S, Yanagawa H, Kaneko S, Yamashita T, Honda M

PLoS Pathog 21(12): e1013776, 2025

PMID: 41406170

<https://doi.org/10.1371/journal.ppat.1013776>

ネトリン-1 は肝細胞感染における HBV の接着と侵入を阻害する

2026-01-16

Structural insights into the role of eIF3 in translation mediated by the HCV IRES

Iwasaki W, Kashiwagi K, Sakamoto A, Nishimoto M, Takahashi M, Machida K, Imataka H, Matsumoto A, Shichino Y, Iwasaki S, Imami K, Ito T

Proc Natl Acad Sci U S A 122(49): e2505538122, 2025

PMID:41337487

HCV IRES を介した翻訳における eIF3 の役割に関する構造的知見

2026-01-17

The prion-like characteristic of ORF3 contributes to virion release and pathogenesis of hepatitis E virus

Wang Y, Tian H, Shi N, Wu C, Huang Y, Yang Y, Ding Q, Zheng X, Zhao Q, Hu Z, Luo J, Feng L, Xu L, Tuite M F, Chen H, Nan Y

Proc Natl Acad Sci U S A 122(49): e2511801122, 2025

PMID:41343667

HEV ORF3 タンパク質のプリオン様特性は、HEV 粒子の放出と病原性に寄与する

2026-01-18

Antibody responses to a highly conserved peptide in HCV E2 protein correlate with chronicity or spontaneous clearance of HCV infection

He Y, Zhong L, DeSilva A R, Kwok K S, Deng L, Virata M L, Yan H, Scott D, Major M, Alter H J, Zhang P

Proc Natl Acad Sci U S A 123(1): e2522340122, 2026

PMID:41481431

HCV E2 タンパク質中の高度に保存されたペプチドに対する抗体反応は、HCV 感染の慢性化または自然消失と関連している

2026-01-19

The dynamic states of hepatitis B virus capsid monomers under the impact of different class of capsid-assembly modulators

Askari F S, Mohebbi A

Sci Rep 15:32731, 2025

PMID: 40993170

<https://doi.org/10.1038/s41598-025-18339-6>

異なるクラスのカプシド集合調節因子の影響下における HBV カプシドモノマーの動的状態

2026-01-20

Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with tenofovir alafenamide vs. entecavir

Kim H, Kim J Y, Yoo H J, Kim L Y, Yoo J J, Kim S G, Kim Y S

Sci Rep 15:33872, 2025

PMID: 41028032

<https://doi.org/10.1038/s41598-025-08023-0>

TAF と ETV による治療を受けた慢性 B 型肝炎患者の腎転帰に関する全国的解析

2026-01-21

Bioinformatics identification of key genes correlating NOD1 and Endoplasmic reticulum stress in hepatitis B virus-induced acute liver failure

Deng F, Jiang W, Wang N, Wu Y, Xu J, Hou R, Jia F

Sci Rep 15:35919, 2025

PMID: 41087615

<https://doi.org/10.1038/s41598-025-19813-x>

HBV-ALF における NOD1 と小胞体ストレスに関連する主要遺伝子のバイオインフォマティクス解析

2026-01-22

Identification of key biomarkers associated with necroptosis and immune infiltration in hepatitis B virus-related acute-on-chronic liver failure

Cao C, Luo D, Xie X, Dou C

Sci Rep 15:37440, 2025

PMID: 41145553

<https://doi.org/10.1038/s41598-025-21273-2>

HBV-ACLF におけるネクロプトーシスおよび免疫浸潤に関連する主要バイオマーカーの同定

2026-01-23

Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B

He T, Chen M, Liu M, Zhang L, Sun H, Zhang L, Li A, Zeng W, Ling N, Shi X, He H, Peng M, Cai D, Hu P, Zhang D, Lan Y, Ren H

Gut 2025-336655, Dec 24 [Epub ahead of print]

PMID:41443982

24 週間の抗 PD-1 抗体療法は、慢性 B 型肝炎患者において HBs 抗原の減少を促進し、同時に HBV 特異的 T 細胞応答を増強した

2026-01-24

Circulating HBV RNA and HBsAg seroconversion in patients with chronic HBV infection: a long-term follow-up study starting from childhood in Taiwan

Wu J F, Hsu C T, Tai C S, Chang K C, Chu C Y, Chiu Y C, Chen H L, Ni Y H, Chang M H

Gut 2025-337123, Dec 19 [Epub ahead of print]

PMID:41419305

慢性 HBV 感染患者における血中 HBV RNA と HBsAg セロコンバージョン：台湾における小児期からの長期追跡調査

2026-01-25

Challenges in accurate HDV RNA quantification: inter-assay variability and the impact of thermal shock

Perez-Garcia F, Virseda-Berdices A, Pita-Martinez C, Munoz Monte M, Sepulveda-Crespo D, Codina H, Alonso R, Mesones L, Rodrigo S, Macias J, Real L M, Cuadros-Gonzalez J, Martinez I, Resino S

J Clin Microbiol e01517-25, Dec 31 [Epub ahead of print]

PMID: 41474328

<https://doi.org/10.1128/jcm.01517-25>

HDV RNA の正確な定量における課題：アッセイ間のばらつきと熱ショックの影響

2026-01-26

Antigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independent

Mimms J L, Sinnis-Bourozikas A, Felbinger N R, Frumento N, Paul H T, Patel A H, Keck Z, Fong S K H, Law M, Urbanowicz R A, Tarr A W, Ball J K, Pierce B G, Bailey J R

J Gen Virol 107(1):002201, 2026

PMID: 41527886

<https://doi.org/10.1099/jgv.0.002201>

HCV E1E2 糖タンパク質中和部位の抗原性は遺伝子型に依存しない

2026-01-27

Epidemiology and clinical characteristics of rat hepatitis E virus infection in humans

Situ J, Wong T C, Wu S, Li Z, Shun E H K, Ho S F S, Yip C C Y, Lo K H Y, Tsoi J Y H, Ma W, Lo A T K, Yiu J, Ng E Y T, Kwong M Y, Ip C Y L, Chung H L, Chew N F S, Liang Y, Mao W, Ma X, Hui D T Y, Wong S C Y, Chan K M, Cheung C Y, Kwong T S, Lung D C, Cheng V C C, Yuen K Y, Sridhar S

J Infect 92(1):106667, 2026

PMID:41421648

ヒトにおけるラット HEV 感染の疫学と臨床的特徴

2026-01-28

Immunological characterization of hepatitis B core antigen antibody among vaccinated adults lacking hepatitis B surface antigen in Ethiopia: A multicenter facility-based study

Aduagna A, Abebaw D, Teffera Z H, Kindie Y, Belay W Y, Mihiret G T, Kassaw A B, Abera M B, Abebe G, Alem A, Geto Z, Seid M A, Yesuf H A, Asfaw M S, Jemal M

Sci Rep 15:41052, 2025

PMID: 41266567

<https://doi.org/10.1038/s41598-025-25018-z>

エチオピアの HBs 抗原陰性ワクチン接種成人における HBc 抗体の免疫学的特性評価: 多施設共同研究

2026-01-29

Serum osteocalcin is associated with the presence of hepatic steatosis in Chinese patients with chronic hepatitis B

He Y, Tong L, Zhou Y, Xie F, Tian N, Xie W

Sci Rep 15:41641, 2025

PMID: 41285914

<https://doi.org/10.1038/s41598-025-25625-w>

血清オステオカルシンは、慢性 B 型肝炎の中国人患者における脂肪肝の存在と関連している

2026-01-30

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort

Suda G, Baba M, Yamamoto Y, Yoshida S, Muranaka T, Meguro T, Terashita K, Ito J, Kobayashi T, Izumi T, Takagi T, Hosoda S, Yamada R, Fu Q, Yang Z, Yokoyama D, Tanaka T, Meno A, Yasuura N, Kitagataya T, Ohara M, Kawagishi N, Nakai M, Sho T, Ogawa K, Sakamoto N

Sci Rep 15:42628, 2025

PMID: 41315792

<https://doi.org/10.1038/s41598-025-26891-4>

前向き多施設コホートの後ろ向き解析に基づく、慢性 C 型肝炎の日本人患者における SOF/VEL の簡易モニタリング

2026-01-31

Genomic surveillance of HBV and HDV reveals genotype-specific risk of liver disease in central Vietnam

Cao L C, Xinh T T T, Phuoc D N, Dung N T, Loan T T K, Van Duc P, Huyen D T, Linh L T K, Song L H, Velavan T P

Sci Rep 15:43491, 2025

PMID: 41372328

<https://doi.org/10.1038/s41598-025-31423-1>

HBV と HDV のゲノム調査により、ベトナム中部における肝疾患の遺伝子型特異的リスクが明らかになった

2026-01-32

Network pharmacology and molecular docking reveal antiviral mechanisms of silver nanoparticles synthesized by *Oscillatoria* sp. against HCV pathogenesis

Azmy L, Al-Olayan E, Abdelhamid M A A, Ibraheem I B M, Zayed A, Gheda S F, Youssif K A, Abou-Zied H A, Abdelmohsen U R, Pack S P, Khalifa H O, Elsayed K N M

Sci Rep 15:43891, 2025

PMID: 41387476

<https://doi.org/10.1038/s41598-025-26310-8>

ネットワーク薬理学と分子ドッキングにより、*Oscillatoria* 属によって合成された銀ナノ粒子の HCV 病原性に対する抗ウイルスメカニズムが明らかになった

2026-01-33

Global prevalence of occult hepatitis B virus infection in HBcAb-positive individuals: a systematic review and meta-analysis

Yang Y, Xing H, Wu G, Zhao Y

Sci Rep 15:44244, 2025

PMID: 41422317

<https://doi.org/10.1038/s41598-025-23207-4>

HBc 抗体陽性者における occult HBV 感染 (OBI) の世界的有病率: 系統的レビューとメタ分析

2026-01-34

Metabolic dynamics and stage-specific biomarkers in chronic HBV infection: a metabolomics study

Liu L, Zhu Z, Jin W, Su X, Deng Z, Li C

BMC Gastroenterol 25:744, 2025

PMID: 41120959

<https://doi.org/10.1186/s12876-025-04332-w>

慢性 HBV 感染における代謝動態と病期特異的バイオマーカー: メタボロミクス研究

2026-01-35

Efficacy of TDF, TAF, TMF, and TDF-to-TAF switch in chronic hepatitis B: a network meta-analysis

Yang S, Lin Y, Zhang H, Liang Y, Yuan W, Wang X, Lin W, Hong W, Su Z, Zeng D, Yu X

BMC Gastroenterol 25:760, 2025

PMID: 41136921

<https://doi.org/10.1186/s12876-025-04289-w>

慢性 B 型肝炎における TDF、TAF、TMF、および TDF から TAF への切り替えの有効性: ネットワークメタ分析

2026-01-36

Characteristics of extracellular vesicle-derived lncRNAs during the progression of HBV-related hepatocellular carcinoma

Ma Y, Lou C, Liang J, Guo C, Zhang J, Lu C, Zhang J, Gao Y

BMC Cancer 25:1768, 2025

PMID: 41239305

<https://doi.org/10.1186/s12885-025-15237-y>

HBV 関連肝細胞癌の進行過程における細胞外小胞由来 lncRNA の特徴

2026-01-37

Pangenotypic glecaprevir/pibrentasvir therapy for chronic hepatitis C in children

Pawlowska M, Zarebska-Michaluk D, Dobrowolska K, Moppert J, Kalinowska Z, Pokorska-Spiwak M, Mania A, Majda-Stanislawski E, Flisiak R

Pediatr Infect Dis J 005069, Nov 20 [Epub ahead of print] PMID:41261401

小児慢性 C 型肝炎に対する汎遺伝子型 GLE/PIB 療法

2026-01-38

Serology change-based clinical interpretation of indeterminate serostatus post-hepatitis B virus infection in people living with HIV

Kinai E, Ishikura M, Miyashita R, Yamaguchi T, Chikasawa Y, Ichiki A, Sekiya R, Bingo M, Muramatsu T, Yotsumoto M, Hagiwara T, Amano K

PLoS One 20(11): e0336924, 2025

PMID: 41264590

<https://doi.org/10.1371/journal.pone.0336924>

HIV 感染者における HBV 感染後の不確定血清学的状態の血清学的変化に基づく臨床的解釈

2026-01-39

The ratio of GGT to PLT indices is a predictive factor for the progression of liver fibrosis in NA-treated chronic hepatitis B patients with advanced fibrosis plus PEG-IFN α -2a therapy: a case-control study

Li L, Li H, Zhao Y, Shi L, Suwanbai M, Ren L, Li G, Pan X

BMC Gastroenterol 025-04508-4, Dec 10 [Epub ahead of print] PMID: 41372812

<https://doi.org/10.1186/s12876-025-04508-4>

GGT と PLT の比率は、NA 治療後の肝線維化が進行した慢性 B 型肝炎患者に PEG-IFN α -2a 療法を加えた場合の肝線維化の進行の予測因子である：症例対照研究

2026-01-40

Development of a nomogram for predicting the long-term risk of hepatocellular carcinoma after antiviral treatment for hepatitis C

Li J, Yangjin B, Zhu C, Xu W, He Y

BMC Gastroenterol 25:860, 2025

PMID: 41398933

<https://doi.org/10.1186/s12876-025-04412-x>

C 型肝炎の抗ウイルス治療後の肝細胞癌の長期リスクを予測するためのノモグラムの開発

2026-01-41

Low-level viremia increases the risk of adverse long-term outcomes in entecavir-treated patients with chronic hepatitis B

Ji D, He M W, Wang W C, Han W, Chen Y, Liu Y, Li L, Li X Y, Guo Y F, Yang W C, Dong Z, Wang C Y, Xu J, Tan L, Lau G, Yang Y

Antiviral Res 246:106334, 2026

PMID:41412547

微量のウイルス残存が、エンテカビル治療中の慢性B型肝炎患者の長期予後を悪化させる

2026-01-42

Hepatitis B virus genomic variability & HBV-related disease outcomes: A molecular epidemiology perspective

Bousali M, Papatheodoridis G, Bletsas M, Paraskevis D, Karamitros T

J Med Virol 97(12): e70760, 2025

PMID: 41424412

<https://doi.org/10.1002/jmv.70760>

HBV のゲノム変異性と HBV 関連疾患の転帰: 分子疫学的視点

2026-01-43

Coexistence of HBsAg and anti-HBs predicts severe hepatic fibrosis in untreated children with hepatitis B virus infection

Yao Z, Gu Y, Lai X, Luo J, Peng S

J Med Virol 97(12): e70763, 2025

PMID:41420401

未治療の小児B型肝炎におけるHBs抗原と抗HBsの共存は、重度の肝線維化を示唆する

2026-01-44

Genetic influence of IFN- γ gene polymorphisms on hepatitis C progression and recovery

Rafiq K, Khan S, Khan M B, Yaqoob M, Adnan M

J Virol Methods 342:115337, 2026

PMID:41506323

IFN- γ 遺伝子多型のC型肝炎の進行と回復に対する遺伝的影響

2026-01-45

Viral surveillance of invasive mammals in New Zealand reveals unique viral lineages reflecting their introduction history

French R K, Pichlmüller F, Waller S J, Dubrulle J, Tuxford J, Veale A, Geoghegan J L

J Virol e01440-25, Dec 19 [Epub ahead of print]

PMID: 41416836

<https://doi.org/10.1128/jvi.01440-25>

ニュージーランドにおける外来哺乳類のウイルス調査により、その導入の歴史を反映した独自のウイルス系統が明らかになった

2026-01-46

Hepatitis E virus screening in Irish blood donors: Seven years of individual donation nucleic acid testing reveals a frequent blood donor infection-but what is the risk?

O'Flaherty N, Mullarkey M, Burke L, Williams P, Dean J, Szulc J, Waters A

Transfus Med 70047, Dec 12 [Epub ahead of print]

PMID: 41386707

<https://doi.org/10.1111/tme.70047>

アイルランド献血者における HEV 検査: 7 年間にわたる個別 NAT により、献血者感染が頻繁に発生していることが判明したが、そのリスクはどうか?

2026-01-47

Immune memory assessment three years following a single dose of hepatitis A vaccine at 12, 13 or 19 months of age

Febriani Y, Ursu M M, Sauvageau C, Kegbevi K B, Quach C, Desjardins M, Bestman-Smith J, Gilca V, Brousseau N

Vaccine 73:128144, 2026

PMID: 41453243

<https://doi.org/10.1016/j.vaccine.2025.128144>

12 ヶ月齢、13 ヶ月齢、または 19 ヶ月齢で A 型肝炎ワクチンを 1 回接種してから 3 年後の免疫記憶の評価

2026-01-48

Optimization of lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes for *in vivo* delivery of a CRISPR/Cas9 system targeting hepatitis B virus

Akhter R, Kitab B, Kayesh M E H, Shimizu R, Onuma H, Yamamoto N, Ogawa S, Sugiyama M, Tanaka Y, Sato Y, Kohara M, Tsukiyama-Kohara K

Virus Res 363:199682, 2026

PMID: 41453683

<https://doi.org/10.1016/j.virusres.2025.199682>

HBV を標的とする CRISPR/Cas9 システムの体内送達のためのリボ核タンパク質-オリゴヌクレオチド複合体を搭載した脂質ナノ粒子の最適化

2026-01-49

Beyond burden: a Quality of Care Index (QCI) assessment of hepatitis B in 204 countries, 1990-2021

Hu Y, Qi X, Jiang Y, Jiang W

Virus Res 364:199683, 2026

PMID: 41485714

<https://doi.org/10.1016/j.virusres.2025.199683>

負担を超えて: 1990 年から 2021 年までの 204 か国における B 型肝炎の医療の質指標 (QCI) 評価

2026-01-50

Innate and adaptive immune responses in hepatitis C virus infections

Kishida Y

Virus Res 364:199685, 2026

PMID: 41500336

<https://doi.org/10.1016/j.virusres.2026.199685>

HCV 感染における自然免疫と獲得免疫応答

2026-01-51

Spatial variation in risk factors for anti-hepatitis E antibody titers in a population-based German study

Diaz A C, Ittermann T, Nauck M, Petersmann A, Volzke H, Schauer B

Sci Rep 15:41463, 2025

PMID: 41272160

<https://doi.org/10.1038/s41598-025-26850-z>

ドイツの人口ベース研究における HEV 抗体価の危険因子に関する空間的変動

2026-01-52

Unraveling a mechanism underlying hepatitis E-associated kidney disease: Discovery of HEV ORF2 capsid protein-associated immune complex glomerulonephritis

Leblond A L

Pathologie (Heidelb) 47(Suppl 1): S27–31, 2026

PMID: 41284019

<https://doi.org/10.1007/s00292-025-01499-7>

E 型肝炎関連腎疾患の発症メカニズムの解明: HEV ORF2 カプシドタンパク質関連免疫複合体糸球体腎炎の発見

2026-01-53

Efficacy of DPMAS combined with PE in improving survival outcomes of patients with acute hepatitis E-induced liver failure: A retrospective cohort analysis

Tang R, Ji Y, Yao H, Zhou X, Feng D, Cheung E C, Liu H, Wang K

iLIVER 4(4):100203, 2025

PMID: 41362691

<https://doi.org/10.1016/j.iliver.2025.100203>

急性 E 型肝炎誘発性肝不全患者の生存転帰改善における DPMAS と PE の併用療法の有効性: 後ろ向きコホート分析

2026-01-54

Multiplex serological screening of wild boar as sentinels of emerging zoonoses: HEV, WNV, and TBEV distribution in Saxony, Germany

Kasper L, Sadeghi B, Deutschmann P, Stoek F, Ziegler U, Balkema-Buschmann A, Groschup M H, Eiden M

One Health 21:101283, 2025

PMID: 41368441

<https://doi.org/10.1016/j.onehlt.2025.101283>

新興人獣共通感染症の監視指標としてのイノシシを用いた多重血清学的スクリーニング: ドイツ、ザクセン州における HEV、WNV、TBEV の分布

2026-01-55

Patagonian shellfish and hidden threats: unveiling the viral landscape and the first quantitative microbial risk assessment of Argentine bivalve mollusks

Frydman C, Parreño V, Cap M, Galeano S, Signorini Porchietto M, Mozgovoj M

Food Microbiol 135:104981, 2026

PMID:41344773

パタゴニア産貝類と隠れた脅威: ウイルス分布の解明とアルゼンチン産二枚貝における初の定量的微生物リスク評価

2026-01-56

Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China

Zhang L, Zhang Q, Liu J, Wu W, Jiang Z, Yan B, Cao Q, Liu H, Pan H, Lv J, Feng Y, Xu F, Huang S, Xu A

Hum Vaccin Immunother 21(1):2448882, 2025

PMID: 39797410

<https://doi.org/10.1080/21645515.2024.2448882>

臨床的に安定期にある慢性B型肝炎患者における HepE Hecolin®の免疫原性と安全性：中国におけるオープンラベル試験

2026-01-57

No evidence of hepatitis E virus-associated central nervous system infections in a Vietnamese multicenter cohort

Dong D V, Sang V V, Hoan N X, Linh N T K, Quang H X, Lien T T, Trang V D, Song L H, Velavan T P

IJID Reg 17:100793, 2025

PMID: 41280343

<https://doi.org/10.1016/j.ijregi.2025.100793>

ベトナムの多施設コホート研究において、HEV 関連中枢神経系感染症の証拠は認められなかった

2026-01-58

Epidemiology and seroprevalence of hepatitis E Virus in Nigeria and its African context: a review and one health perspective

Olowu B I, Tinubu O B, Solesi O O, Ochi E, Ahmed S O, Zakariya M E

Infez Med 33(4):370–81, 2025

PMID: 41384158

<https://doi.org/10.53854/liim-3304-2>

ナイジェリアとアフリカ地域における HEV の疫学と血清学的有病率：レビューとワンヘルス視点

2026-01-59

Viral hepatitis as a differential diagnosis of yellow fever suspected cases in Cameroon: Prevalence and molecular characterization

Modiyinji A F, Simo H T, Mounchili-Njifon A, Moumbeket-Yifomnjou M H, Djomo L F, Yabi D N, Odi J G, Machuetum G L, Ngu A N, Njouom R

IJID Reg 17:100732, 2025

PMID: 41473503

<https://doi.org/10.1016/j.ijregi.2025.100732>

カメルーンにおける黄熱病疑い症例の鑑別診断としてのウイルス性肝炎：有病率と分子生物学的特徴

2026-01-60

Hepatitis E virus in immunocompromised children in Argentina: first report from a high-risk group

Acosta J, Costaguta G, Gardiol D, Álvarez F, Costaguta A, Cavatorta A L

Virol J 23:2, 2026

PMID: 41331869

<https://doi.org/10.1186/s12985-025-03037-6>

アルゼンチンの免疫不全児における HEV：高リスク群からの最初の報告